Harding v. Cordis Corp.

2021 IL App (1st) 210032, 196 N.E.3d 514, 458 Ill. Dec. 210
CourtAppellate Court of Illinois
DecidedDecember 3, 2021
Docket1-21-0032
StatusPublished
Cited by3 cases

This text of 2021 IL App (1st) 210032 (Harding v. Cordis Corp.) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Harding v. Cordis Corp., 2021 IL App (1st) 210032, 196 N.E.3d 514, 458 Ill. Dec. 210 (Ill. Ct. App. 2021).

Opinion

2021 IL App (1st) 210032

SIXTH DIVISION December 3, 2021

IN THE APPELLATE COURT OF ILLINOIS FIRST DISTRICT

No. 1-21-0032

PATTIE A. HARDING, ) ) Appeal from the Plaintiff-Appellee, ) Circuit Court of ) Cook County. v. ) ) CORDIS CORPORATION, a Florida Corporation; ) JOHNSON & JOHNSON, a New Jersey Corporation; ) No. 17 L 8306 CONFLUENT MEDICAL TECHNOLOGIES, INC., a ) Delaware Corporation; and GAIL SUSAN SMITH, M.D., ) ) Defendants, ) The Honorable ) Gerald Cleary, (Confluent Medical Technologies, Inc., Defendant- ) Judge Presiding. Appellant). )

JUSTICE MIKVA delivered the judgment of the court, with opinion. Presiding Justice Pierce and Justice Oden Johnson concurred in the judgment and opinion.

OPINION

¶1 The question before us is whether a defendant who manufactures a custom component of

a medical device that is alleged to have caused injury to an Illinois resident has sufficient minimum

contacts with this state to subject itself to the jurisdiction of our courts. This defendant knew the

medical device was sold in the United States but not which specific states it was sold in. The

defendant also sold other similar products directly to Illinois. We hold that our courts do have

jurisdiction over this defendant for the reasons outlined in this opinion. No. 1-21-0032

¶2 The plaintiff, Pattie A. Harding, brought a suit against several defendants, including

Confluent Medical Technologies, Inc. (Confluent), after suffering injuries due to what she alleged

was a defective medical device manufactured, sold, and implanted by the defendants. Confluent

moved, unsuccessfully, to dismiss the claims against it for a lack of personal jurisdiction.

Confluent now appeals, arguing that it lacks the requisite minimum contacts with Illinois for the

State to exercise personal jurisdiction over it. For the following reasons, we affirm.

¶3 I. BACKGROUND

¶4 Ms. Harding alleged in her complaint that in June 2010 she suffered personal injuries as a

direct and proximate result of a defective inferior vena cava (IVC) filter. According to the

complaint, an IVC filter is a medical device “designed to filter or ‘catch’ blood clots that travel

from the extremities to the heart and lungs.” Computerized tomography scans performed in

December 2015 and February 2016 revealed that “tines” of the IVC filter had perforated the wall

of Ms. Harding’s inferior vena cava, that the filter had migrated and fractured, and that a piece of

the filter was lodged in Ms. Harding’s heart.

¶5 Ms. Harding alleged that Confluent was incorporated in Delaware and headquartered in

California. She further alleged that Confluent was an affiliate of Cordis Corporation (Cordis) and

was involved in the manufacture and design of the IVC filters. Ms. Harding alleged that “Confluent

ha[d] conducted business and derived substantial revenue from within the State of Illinois, from

including, but not limited to, its business activities related to [the] IVC filters.”

¶6 Ms. Harding also alleged that Confluent and Cordis:

“were engaged in the business of researching, developing, designing, setting specifications

for, licensing, manufacturing, preparing, compounding, assembling, processing, selling,

distributing, marketing, and/or introducing into interstate commerce and into the State of

-2- No. 1-21-0032

Illinois, either directly or indirectly through third parties or related entities, the Cordis IVC

filters—specifically, the OptEase filter—to be implanted in patients throughout the United

States, including Illinois, and including the Cordis IVC filters implanted in [Ms. Harding],

and derived substantial income from doing business in Illinois.”

¶7 Ms. Harding also states in her brief that “[t]he OptEase IVC filter medical device was

comprised of the nitinol filter manufactured by Confluent, the delivery system, instructions for

use, and other labeling materials,” suggesting that the nitinol filter custom manufactured by

Confluent for Cordis was the significant component of Cordis’s OptEase filter. Confluent did not

refute this characterization of its product.

¶8 Ms. Harding’s claims against Confluent and Cordis included strict products liability based

on a product defect, an inadequate warning, and a manufacturing defect; negligence; negligent

misrepresentation; fraudulent misrepresentation; fraudulent concealment; and breaches of both

express warranty and implied warranty of merchantability. She asked for general noneconomic

damages for past and future pain and suffering, emotional distress, and loss of enjoyment of life,

plus special economic damages for past and future medical expenses, disgorgement of profits,

restitution, statutory damages, costs, and pre- and post-judgment interest.

¶9 Confluent moved to dismiss Ms. Harding’s complaint under sections 2-301 and 2-619 of

the Code of Civil Procedure (Code) (735 ILCS 5/2-301, 2-619 (West 2018)). It argued that Ms.

Harding had failed to allege any facts that would allow the circuit court to exercise personal

jurisdiction over it. Confluent stated that it “did not design, manufacture, market, sell or distribute

any portion of the OptEase IVC filter at issue in this case in Illinois” and that Ms. Harding therefore

could not show that Confluent “purposefully directed its activities at Illinois” or that the claims

against Confluent “arose out of or relate[d] to Confluent’s contacts with Illinois.”

-3- No. 1-21-0032

¶ 10 Confluent explained that, although it did manufacture nitinol component parts used in

Cordis’s OptEase filter, “using the manufacturing processes from Cordis and based on the design

and specifications from Cordis,” it did so in California until 2010 and thereafter in Costa Rica.

According to Confluent, it “sells the component parts directly to Cordis and ships them to Juarez,

Mexico.” Confluent maintained that it did not sell, distribute, or manufacture nitinol components

for IVC filters in Illinois; it did not know where Cordis marketed or sold its IVC filters; it

maintained no offices, agencies, places of business, post office boxes, or telephone listings in

Illinois; it did not have any interest in any property in Illinois; it did not pay taxes or have

employees or agents who resided in Illinois; and it did not engage in the direct solicitation of

business or directly advertise any goods or services in Illinois. Confluent acknowledged that it did

“sell a very small amount of its products in Illinois” but insisted both that “none of th[o]se products

[were] related to the IVC filters at issue in this litigation” and that sales of those products in Illinois

represented only a de minimis amount (less than 0.05%) of its total sales.

¶ 11 Confluent attached to its motion the affidavit of its plant controller Jorge Kau, who attested

to all of the above factual information. The only discrepancy between the facts as presented in

Confluent’s motion and Mr. Kau’s affidavit was that Mr. Kau said that Confluent’s nitinol-product

sales in Illinois made up 0.5% of its total sales, rather than 0.05%.

¶ 12 During a September 24, 2019, hearing in the circuit court, the parties discussed Confluent’s

proposed stipulation that, during the time Confluent had manufactured the nitinol component for

use in Cordis’s OptEase filters, it “was generally aware that Cordis was selling the IVC filters in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Preciado v. Freightliner Custom Chassis Corp.
California Court of Appeal, 2023
Adams v. Aircraft Spruce & Specialty Co.
345 Conn. 312 (Supreme Court of Connecticut, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
2021 IL App (1st) 210032, 196 N.E.3d 514, 458 Ill. Dec. 210, Counsel Stack Legal Research, https://law.counselstack.com/opinion/harding-v-cordis-corp-illappct-2021.